MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 16, 2005; DOI: 10.1124/mol.105.016121


0026-895X/05/6805-1423-1430$20.00
Mol Pharmacol 68:1423-1430, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.016121v1
68/5/1423    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duryee, M. J.
Right arrow Articles by Thiele, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duryee, M. J.
Right arrow Articles by Thiele, G. M.

Scavenger Receptors on Sinusoidal Liver Endothelial Cells Are Involved in the Uptake of Aldehyde-Modified Proteins

Michael J. Duryee, Thomas L. Freeman, Monte S. Willis1, Carlos D. Hunter, Bartlett C. Hamilton, III, Hiroshi Suzuki2, Dean J. Tuma, Lynell W. Klassen, and Geoffrey M. Thiele

Departments of Internal Medicine (M.J.D., T.L.F., C.D.H., B.C.H., D.J.T., L.W.K., G.M.T.) and Pathology and Microbiology (G.M.T.), University of Nebraska Medical Center, Omaha, Nebraska; and Veterans Administration Alcohol Research Center, Omaha Veterans Administration Medical Center, Omaha, Nebraska (M.J.D., T.L.F., M.S., C.D.H., B.C.H., H.S., D.J.T., L.W.K., G.M.T.)

Scavenger receptors on sinusoidal liver endothelial cells (SECs) eliminate potentially harmful modified proteins circulating through the liver. It was shown recently that aldehyde-modified proteins bind to scavenger receptors and are associated with the development/progression of alcoholic liver diseases. For these studies, rat livers were perfused in situ with 125I-formaldehyde-bovine serum albumin (f-Alb) or 125I-malondialdehyde-acetaldehyde-bovine serum albumin (MAA-Alb) in the presence of known scavenger receptor ligands as inhibitors. Reverse transcription-polymerase chain reaction (RT-PCR) analysis and scavenger receptor Type A (SRA) knock-out mice were used to assess the role of these receptors in mediating immune responses. The degradation of 125I-f-Alb or 125I-MAA-Alb in whole livers and isolated SECs can be inhibited by known scavenger receptor ligands, including f-Alb, maleylated bovine albumin, and fucoidan. 125I-f-Alb could not be completely inhibited by MAA-Alb. In contrast, 125I-MAA-Alb was only partially inhibited with advanced glycosylated endproduct albumin. RT-PCR data show the presence of a number of scavenger receptors on SECs that may be responsible for the binding of MAA-modified proteins. SRA seems to be one of these receptors involved in the effects mediated by MAA-modified proteins. In a study using SRA knockout mice, it was shown that a decreased antibody response to MAA-Alb resulted. By RT-PCR, CD36, LOX-1, and SR-AI are the scavenger receptors most likely involved in the degradation of MAA-Alb.


Received June 28, 2005; accepted August 15, 2005

Address correspondence to: Michael J. Duryee, Omaha VA Medical Center, Research Services 151, Room 325, 4101 Woolworth Avenue, Omaha, NE 68105. E-mail: mduryee{at}unmc.edu




This article has been cited by other articles:


Home page
FASEB J.Home page
E. Herczenik and M. F. B. G. Gebbink
Molecular and cellular aspects of protein misfolding and disease
FASEB J, July 1, 2008; 22(7): 2115 - 2133.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics